Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 0.38 |
| ▸ | CNR1 | P21554 | 14/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20047683 | 0.88 | CNR2 (0.34) | CNR2CNR1 | |
| SCHEMBL20047682 | 0.86 | CNR2 (0.37) | CNR2CNR1 | |
| SCHEMBL20047619 | 0.84 | CNR2 (0.32) | CNR2CNR1 | |
| SCHEMBL20047621 | 0.82 | PDE4A (0.33) | — | |
| SCHEMBL20047622 | 0.82 | CNR2 (0.31) | CNR2CNR1 | |
| SCHEMBL20047685 | 0.81 | CNR1 (0.35) | CNR2CNR1 | |
| SCHEMBL21161253 | 0.79 | KDM4E (0.31) | ESR1 | |
| SCHEMBL20047669 | 0.79 | TLR8 (0.31) | — | |
| SCHEMBL23502551 | 0.79 | CNR2 (0.38) | CNR2CNR1ESR1 | |
| SCHEMBL23502550 | 0.78 | PDE4A (0.31) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689391-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190194216-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194216-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | SLC10A1, NR1H4, GPBAR1 | CNR2 471/4885CNR1 393/4885ESR1 1588/4885 |
| US-10689391-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | SLC10A1, NR1H4, GPBAR1 | CNR2 471/4885CNR1 393/4885ESR1 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.